Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1996 Sep;61(3):239–241. doi: 10.1136/jnnp.61.3.239

More immunotherapy for multiple sclerosis.

R A Hughes, B Sharrack
PMCID: PMC486544  PMID: 8795592

Full text

PDF
239

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bastianello S., Pozzilli C., D'Andrea F., Millefiorini E., Trojano M., Morino S., Gasperini C., Bozzao A., Gallucci M., Andreula C. A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. Can J Neurol Sci. 1994 Aug;21(3):266–270. doi: 10.1017/s0317167100041263. [DOI] [PubMed] [Google Scholar]
  2. Beutler E., Sipe J. C., Romine J. S., Koziol J. A., McMillan R., Zyroff J. The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A. 1996 Feb 20;93(4):1716–1720. doi: 10.1073/pnas.93.4.1716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bornstein M. B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil-Smoller S., Spada V. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987 Aug 13;317(7):408–414. doi: 10.1056/NEJM198708133170703. [DOI] [PubMed] [Google Scholar]
  4. Filippi M., Horsfield M. A., Morrissey S. P., MacManus D. G., Rudge P., McDonald W. I., Miller D. H. Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology. 1994 Apr;44(4):635–641. doi: 10.1212/wnl.44.4.635. [DOI] [PubMed] [Google Scholar]
  5. Filippi M., Paty D. W., Kappos L., Barkhof F., Compston D. A., Thompson A. J., Zhao G. J., Wiles C. M., McDonald W. I., Miller D. H. Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology. 1995 Feb;45(2):255–260. doi: 10.1212/wnl.45.2.255. [DOI] [PubMed] [Google Scholar]
  6. Francis D. A., Bain P., Swan A. V., Hughes R. A. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991 Mar;48(3):299–301. doi: 10.1001/archneur.1991.00530150067020. [DOI] [PubMed] [Google Scholar]
  7. Goodkin D. E., Cookfair D., Wende K., Bourdette D., Pullicino P., Scherokman B., Whitham R. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 1992 Apr;42(4):859–863. doi: 10.1212/wnl.42.4.859. [DOI] [PubMed] [Google Scholar]
  8. Goodkin D. E., Hertsgaard D., Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850–854. [PubMed] [Google Scholar]
  9. Goodkin D. E. Interferon beta-1b. Lancet. 1994 Oct 15;344(8929):1057–1060. doi: 10.1016/s0140-6736(94)91713-2. [DOI] [PubMed] [Google Scholar]
  10. Goodkin D. E. Interferon beta-1b. Lancet. 1994 Dec 17;344(8938):1702–1703. doi: 10.1016/s0140-6736(94)90484-7. [DOI] [PubMed] [Google Scholar]
  11. Goodkin D. E., Rudick R. A., VanderBrug Medendorp S., Daughtry M. M., Schwetz K. M., Fischer J., Van Dyke C. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995 Jan;37(1):30–40. doi: 10.1002/ana.410370108. [DOI] [PubMed] [Google Scholar]
  12. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  13. Hughes R. A. Immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1994 Jan;57(1):3–6. doi: 10.1136/jnnp.57.1.3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  15. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268–1276. doi: 10.1212/wnl.45.7.1268. [DOI] [PubMed] [Google Scholar]
  16. Kappos L., Radü E. W., Bernasconi L., Brunnschweiler H., Hartung H. P., Haas J., Gehlen W., Hartard C., Lagreze H. L., Rüttinger H. Treatment of multiple sclerosis with 15 +/- deoxyspergualin. Design of a controlled study with close MRI-monitoring. Schweiz Arch Neurol Psychiatr (1985) 1993;144(3):198–201. [PubMed] [Google Scholar]
  17. Kidd D., Thorpe J. W., Kendall B. E., Barker G. J., Miller D. H., McDonald W. I., Thompson A. J. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Jan;60(1):15–19. doi: 10.1136/jnnp.60.1.15. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Krapf H., Mauch E., Fetzer U., Laufen H., Kornhuber H. H. Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology. 1995 Feb;37(2):113–119. [PubMed] [Google Scholar]
  19. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  20. McDonald W. I., Miller D. H., Thompson A. J. Are magnetic resonance findings predictive of clinical outcome in therapeutic trials in multiple sclerosis? The dilemma of interferon-beta. Ann Neurol. 1994 Jul;36(1):14–18. doi: 10.1002/ana.410360106. [DOI] [PubMed] [Google Scholar]
  21. Miller D. H., Albert P. S., Barkhof F., Francis G., Frank J. A., Hodgkinson S., Lublin F. D., Paty D. W., Reingold S. C., Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996 Jan;39(1):6–16. doi: 10.1002/ana.410390104. [DOI] [PubMed] [Google Scholar]
  22. Miller D. H. Magnetic resonance in monitoring the treatment of multiple sclerosis. Ann Neurol. 1994;36 (Suppl):S91–S94. doi: 10.1002/ana.410360720. [DOI] [PubMed] [Google Scholar]
  23. Morrissey S. P., Miller D. H., Kendall B. E., Kingsley D. P., Kelly M. A., Francis D. A., MacManus D. G., McDonald W. I. The significance of brain magnetic resonance imaging abnormalities at presentation with clinically isolated syndromes suggestive of multiple sclerosis. A 5-year follow-up study. Brain. 1993 Feb;116(Pt 1):135–146. doi: 10.1093/brain/116.1.135. [DOI] [PubMed] [Google Scholar]
  24. Nuwer M. R., Packwood J. W., Myers L. W., Ellison G. W. Evoked potentials predict the clinical changes in a multiple sclerosis drug study. Neurology. 1987 Nov;37(11):1754–1761. doi: 10.1212/wnl.37.11.1754. [DOI] [PubMed] [Google Scholar]
  25. Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  26. Polman C. H., Dahlke F., Thompson A. J., Ghazi M., Kappos L., Miltenburger C., Pozilli C. Interferon beta-1b in secondary progressive multiple sclerosis--outline of the clinical trial. Mult Scler. 1995;1 (Suppl 1):S51–S54. [PubMed] [Google Scholar]
  27. Poser C. M., Paty D. W., Scheinberg L., McDonald W. I., Davis F. A., Ebers G. C., Johnson K. P., Sibley W. A., Silberberg D. H., Tourtellotte W. W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol. 1983 Mar;13(3):227–231. doi: 10.1002/ana.410130302. [DOI] [PubMed] [Google Scholar]
  28. Pozzilli C., Bastianello S., Koudriavtseva T., Gasperini C., Bozzao A., Millefiorini E., Galgani S., Buttinelli C., Perciaccante G., Piazza G. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):251–258. doi: 10.1136/jnnp.61.3.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Rudge P. Interferon beta-1b. Lancet. 1994 Nov 26;344(8935):1511–1511. doi: 10.1016/s0140-6736(94)90331-x. [DOI] [PubMed] [Google Scholar]
  30. Sandberg-Wollheim M., Hommes O. R., Hughes R. A., Paty D. W., Abdul-Ahad A. K. Recombinant human interferon beta in the treatment of relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler. 1995;1 (Suppl 1):S48–S50. [PubMed] [Google Scholar]
  31. Sharrack B., Hughes R. A. Clinical scales for multiple sclerosis. J Neurol Sci. 1996 Jan;135(1):1–9. doi: 10.1016/0022-510x(95)00261-y. [DOI] [PubMed] [Google Scholar]
  32. Sipe J. C., Knobler R. L., Braheny S. L., Rice G. P., Panitch H. S., Oldstone M. B. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology. 1984 Oct;34(10):1368–1372. doi: 10.1212/wnl.34.10.1368. [DOI] [PubMed] [Google Scholar]
  33. Sipe J. C., Romine J. S., Koziol J. A., McMillan R., Zyroff J., Beutler E. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet. 1994 Jul 2;344(8914):9–13. doi: 10.1016/s0140-6736(94)91046-4. [DOI] [PubMed] [Google Scholar]
  34. Stone L. A., Smith M. E., Albert P. S., Bash C. N., Maloni H., Frank J. A., McFarland H. F. Blood-brain barrier disruption on contrast-enhanced MRI in patients with mild relapsing-remitting multiple sclerosis: relationship to course, gender, and age. Neurology. 1995 Jun;45(6):1122–1126. doi: 10.1212/wnl.45.6.1122. [DOI] [PubMed] [Google Scholar]
  35. Testa M. A., Simonson D. C. Assesment of quality-of-life outcomes. N Engl J Med. 1996 Mar 28;334(13):835–840. doi: 10.1056/NEJM199603283341306. [DOI] [PubMed] [Google Scholar]
  36. Thompson A. J., Kermode A. G., MacManus D. G., Kendall B. E., Kingsley D. P., Moseley I. F., McDonald W. I. Patterns of disease activity in multiple sclerosis: clinical and magnetic resonance imaging study. BMJ. 1990 Mar 10;300(6725):631–634. doi: 10.1136/bmj.300.6725.631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Whitaker J. N., McFarland H. F., Rudge P., Reingold S. C. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995 Apr;1(1):37–47. doi: 10.1177/135245859500100107. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES